Skip to main content
OpenTrials

Clinical trial condition

Haemophilus Infections

Explore clinical trials studying Haemophilus Infections. Study availability and eligibility vary by location and protocol.

158 public trials 3 recruiting studies
Refine in advanced search Browse all conditions

Haemophilus Infections trial results

Completed

Evaluation of Immunogenicity and Safety of a Booster Dose of Infanrix Hexa™ in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery

NCT02853929

Conditions
Acellular Pertussis, Actinomycetales Infections, Bacterial Infections, +37 more
Locations
  • GSK Investigational Site Carlton, Victoria, Australia
  • GSK Investigational Site Calgary, Alberta, Canada
  • GSK Investigational Site Halifax, Nova Scotia, Canada
  • GSK Investigational Site Montreal, Quebec, Canada
View all 29 locations
View Trial Details
Completed

Immunogenicity and Safety Study of GSK Biologicals' GSK2202083A Vaccine in Healthy Infants at 2, 3 and 4 Months of Age

NCT00970307

Conditions
Acellular Pertussis, Actinomycetales Infections, Bacterial Infections, +33 more
Locations
  • GSK Investigational Site Bydgoszcz, Poland
  • GSK Investigational Site Dębica, Poland
  • GSK Investigational Site Krakow, Poland
  • GSK Investigational Site Krakow, Poland
View Trial Details
Completed

Study to Determine the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals; Infanrix Hexa at 2, 4 and 6 Months of Age in Healthy Infants

NCT02096263

Conditions
Acellular Pertussis, Actinomycetales Infections, Bacterial Infections, +32 more
Locations
  • GSK Investigational Site Tucson, Arizona, United States
  • GSK Investigational Site Fayetteville, Arkansas, United States
  • GSK Investigational Site Anaheim, California, United States
  • GSK Investigational Site Daly City, California, United States
View all 43 locations
View Trial Details
Completed

A Study to Assess the Immunogenicity and Safety of GSK Biologicals' Infanrix-IPV/Hib Vaccine Administered as a Three-dose Vaccination Course at 3, 4.5 and 6 Months of Age and a Booster Dose at 18 Months of Age in Healthy Infants in Russia

NCT02858440

Conditions
Actinomycetales Infections, Bacterial Infections, Bacterial Infections and Mycoses, +25 more
Locations
  • GSK Investigational Site Barnaul, Russia
  • GSK Investigational Site Murmansk, Russia
  • GSK Investigational Site Saint Petersburg, Russia
  • GSK Investigational Site Tomsk, Russia
View Trial Details

Related conditions